Monday, September 30, 2024
Today's Paper

Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID)

Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID)

Tonix's CEO Dr. Lederman shared perspectives from the development of TNX-102 SL for fibromyalgia and the proof-of-concept Phase 2 study of TNX-102 SL for Fibromyalgia-type Long COVID

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

See our subscription options.

Already have an account? Log in here